# OnCo record alveolar-soft-part-sarcoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/alveolar-soft-part-sarcoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "alveolar-soft-part-sarcoma" ;
  schema:name "Alveolar soft part sarcoma"@en ;
  schema:alternateName "ASPS"@en, "ASPSCR1-TFE3 sarcoma"@en ;
  schema:description "Alveolar soft part sarcoma is a rare, slow-growing cancer of young adults driven by a single fusion gene, ASPSCR1-TFE3, that switches on blood vessel growth. Chemotherapy does not work, but drugs that block the tumour's blood supply shrink it, and in 2023 the immunotherapy atezolizumab became the first drug approved for it."@en ;
  schema:url <https://onco.cc/cancers/alveolar-soft-part-sarcoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Alveolar_soft_part_sarcoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Alveolar_soft_part_sarcoma> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/extremity-soft-tissue-sarcoma/>, <https://onco.cc/cancers/synovial-sarcoma/> ;
  onco:pipeline <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/anlotinib/>, <https://onco.cc/trials/nct07548177/>, <https://onco.cc/trials/nct03016819/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:standardOfCare <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/drugs/anlotinib/>, <https://onco.cc/trials/nct03016819/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/limb-salvage-surgery/> .